Cargando…

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

BACKGROUND: Apixaban is an oral, selective, direct factor Xa inhibitor approved for thromboprophylaxis after orthopedic surgery and stroke prevention in patients with atrial fibrillation, and under development for treatment of venous thromboembolism. This study investigated the effect of a gastric a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Upreti, Vijay V, Song, Yan, Wang, Jessie, Byon, Wonkyung, Boyd, Rebecca A, Pursley, Janice M, LaCreta, Frank, Frost, Charles E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637032/ https://www.ncbi.nlm.nih.gov/pubmed/23637566 http://dx.doi.org/10.2147/CPAA.S41999

Ejemplares similares

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost, Charles, et al.
Publicado: (2018)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
por: Byon, Wonkyung, et al.
Publicado: (2019)

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
por: Frost, Charles, et al.
Publicado: (2017)

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
por: Frost, Charles E., et al.
Publicado: (2015)

Model-Based Exposure–Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery
por: Leil, T A, et al.
Publicado: (2014)

The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study
por: Garonzik, Samira, et al.
Publicado: (2019)

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
por: Byon, W, et al.
Publicado: (2017)

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
por: Wong, Pancras C., et al.
Publicado: (2011)

Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
por: Wang, Xiaoli, et al.
Publicado: (2013)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder
por: Merali, Samira J., et al.
Publicado: (2023)

Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data
por: Jamieson, Michael J., et al.
Publicado: (2022)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Pharmacokinetics and efficacy of intravenous famotidine in adult cattle
por: Balcomb, Christie C., et al.
Publicado: (2018)

In Vitro Intestinal Permeability Studies and Pharmacokinetic Evaluation of Famotidine Microemulsion for Oral Delivery
por: Jha, Sajal Kumar, et al.
Publicado: (2014)

Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY
por: Cohen, Alexander T., et al.
Publicado: (2021)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui, Yimin, et al.
Publicado: (2013)

Correction to: Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY
por: Cohen, Alexander T., et al.
Publicado: (2021)

The contribution of apixaban renal clearance to total clearance
por: Frost, Charles, et al.
Publicado: (2015)

Yoghurt as a deglutition aid for oral medication: effects on famotidine powder dissolution rate and pharmacokinetics
por: Gotoh, Yayoi, et al.
Publicado: (2023)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
por: Frost, Charles E., et al.
Publicado: (2021)

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022)

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
por: Zahir, Hamim, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
por: Serpa, Priscila B. S., et al.
Publicado: (2018)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum
Publicado: (2018)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
por: Jakowenko, Nicholas, et al.
Publicado: (2020)

Assessment of Anti‐Xa activity in patients receiving concomitant apixaban with strong p‐glycoprotein inhibitors and statins
por: Milner, Erin, et al.
Publicado: (2022)

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Apixaban and oral implications
por: Lopez-Galindo, Monica, et al.
Publicado: (2015)

A 78-Year-Old Man with a Pulmonary Embolism Who Developed Skin Necrosis 7 Days After Treatment with the Direct Oral Anticoagulant Factor Xa Inhibitor Apixaban
por: Pansuriya, Tusharkumar, et al.
Publicado: (2021)

Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction
por: Yurista, Salva R., et al.
Publicado: (2020)

Population pharmacokinetics and exposure–response analyses of varenicline in adolescent smokers
por: Fediuk, Daryl J., et al.
Publicado: (2021)

No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole
por: Feng, H‐P, et al.
Publicado: (2017)

Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs
por: Herrera, Noelle D., et al.
Publicado: (2021)

Esomeprazole and apixaban pharmacokinetic interactions in healthy rats
por: Jaber, Ali, et al.
Publicado: (2022)

Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients
por: Fung, Winston Wing-Shing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sld0sng8hek64aas1k7d4rjig3